These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8475071)

  • 1. Acquired multicellular-mediated resistance to alkylating agents in cancer.
    Kobayashi H; Man S; Graham CH; Kapitain SJ; Teicher BA; Kerbel RS
    Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3294-8. PubMed ID: 8475071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents.
    Graham CH; Kobayashi H; Stankiewicz KS; Man S; Kapitain SJ; Kerbel RS
    J Natl Cancer Inst; 1994 Jul; 86(13):975-82. PubMed ID: 8007019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells.
    Croix BS; Rak JW; Kapitain S; Sheehan C; Graham CH; Kerbel RS
    J Natl Cancer Inst; 1996 Sep; 88(18):1285-96. PubMed ID: 8797768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents.
    Francia G; Man S; Teicher B; Grasso L; Kerbel RS
    Mol Cell Biol; 2004 Aug; 24(15):6837-49. PubMed ID: 15254249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo.
    Teicher BA; Herman TS; Holden SA; Wang YY; Pfeffer MR; Crawford JW; Frei E
    Science; 1990 Mar; 247(4949 Pt 1):1457-61. PubMed ID: 2108497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors.
    Teicher BA; Chatterjee D; Liu JT; Holden SA; Ara G
    Cancer Chemother Pharmacol; 1993; 32(4):315-9. PubMed ID: 8324874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
    Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
    In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Host distribution and response to antitumor alkylating agents of EMT-6 tumor cells from subcutaneous tumor implants.
    Holden SA; Emi Y; Kakeji Y; Northey D; Teicher BA
    Cancer Chemother Pharmacol; 1997; 40(1):87-93. PubMed ID: 9137536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute in vivo resistance in high-dose therapy.
    Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors.
    Kerbel RS; St Croix B; Florenes VA; Rak J
    Hum Cell; 1996 Dec; 9(4):257-64. PubMed ID: 9183656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA; Holden SA; Herman TS; Frei E
    Semin Oncol; 1991 Apr; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
    Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E
    Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.
    Frei E; Ara G; Teicher B; Bunnell C; Richardson P; Wheeler C; Tew K; Elias A
    Cancer Chemother Pharmacol; 2000; 45(3):239-46. PubMed ID: 10663642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors.
    St Croix B; Man S; Kerbel RS
    Cancer Lett; 1998 Sep; 131(1):35-44. PubMed ID: 9839618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
    Frankel A; Buckman R; Kerbel RS
    Cancer Res; 1997 Jun; 57(12):2388-93. PubMed ID: 9192815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype.
    Chen G; Teicher BA; Frei E
    Cancer Biochem Biophys; 1998 Jun; 16(1-2):139-55. PubMed ID: 9923973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.